Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.01
(1.84%)
CNY 21.01
(1.84%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.05 Billion CNY | -10.01% |
| 2022 | -957.45 Million CNY | -23.78% |
| 2021 | -773.5 Million CNY | -19.71% |
| 2020 | -646.14 Million CNY | 30.39% |
| 2019 | -928.22 Million CNY | -312.14% |
| 2018 | -225.22 Million CNY | -119.25% |
| 2017 | -102.72 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -249.1 Million CNY | -4.09% |
| 2024 Q1 | -205.65 Million CNY | 45.41% |
| 2024 Q2 | -239.32 Million CNY | -16.37% |
| 2023 Q2 | -172.41 Million CNY | 27.89% |
| 2023 FY | -1.05 Billion CNY | -10.01% |
| 2023 Q3 | -259.76 Million CNY | -50.66% |
| 2023 Q1 | -239.09 Million CNY | 8.1% |
| 2023 Q4 | -376.72 Million CNY | -45.03% |
| 2022 Q3 | -266.48 Million CNY | -32.96% |
| 2022 Q2 | -200.42 Million CNY | 8.0% |
| 2022 Q1 | -217.84 Million CNY | 14.54% |
| 2022 FY | -957.45 Million CNY | -23.78% |
| 2022 Q4 | -260.16 Million CNY | 2.37% |
| 2021 FY | -773.5 Million CNY | -19.71% |
| 2021 Q4 | -254.9 Million CNY | -45.42% |
| 2021 Q3 | -175.28 Million CNY | 3.71% |
| 2021 Q2 | -182.04 Million CNY | -15.7% |
| 2021 Q1 | -157.34 Million CNY | 14.45% |
| 2020 Q4 | -183.91 Million CNY | 4.31% |
| 2020 Q3 | -192.19 Million CNY | 0.0% |
| 2020 FY | -646.14 Million CNY | 30.39% |
| 2019 FY | -928.22 Million CNY | -312.14% |
| 2018 FY | -225.22 Million CNY | -119.25% |
| 2017 FY | -102.72 Million CNY | 0.0% |